Skip to main content

Table 2 Immune response genes differentially expressed between pre-treatment and 2 weeks samples from 81 patients treated with anastrozole (18) with a false discovery rate of less than 0.05 and a fold change of greater than 1.5 which included “immune response” as a Gene Ontology category

From: Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer

Genbank accession number

Gene symbol

Gene name

FDR

Fold change

NM_032962

CCL14

Chemokine (C–C motif) ligand 14

2.89E−05

1.84

NM_006288

THY1

Thy-1 cell surface antigen

0.00161

1.73

NM_000609

CXCL12

Chemokine (C-X-C motif) ligand 12

0.000507

1.71

NM_001251

CD68

CD68 antigen

0.001068

1.71

NM_002990

CCL22

Chemokine (C–C motif) ligand 22

0.009704

1.69

NM_001623

AIF1

Allograft inflammatory factor 1 (AIF1)

0.00178

1.67

NM_001025159

CD74

CD74 antigen

0.000583

1.65

NM_004271

LY86

Lymphocyte antigen 86

0.000734

1.65

NM_002123

HLA-DQB1

MHC, class II, DQ beta 1

0.001781

1.65

NM_001290

LDB2

LIM domain binding 2

0.000211

1.63

NM_005516

HLA-E

MHC, class I, E

0.001244

1.63

NM_004512

IL11RA

Interleukin 11 receptor, alpha

0.001573

1.63

NM_002985

CCL5

Chemokine (C–C motif) ligand 5

0.023538

1.61

NM_033554

HLA-DPA1

MHC, class II, DP alpha 1

0.008347

1.61

NM_022555

HLA-DRB3

MHC, class II, DR beta 3

0.008369

1.61

NM_000616

CD4

CD4 antigen (p55)

0.001385

1.59

NM_001242

TNFRSF7

Tumour necrosis factor receptor superfamily 7

0.01003

1.59

NM_022059

CXCL16

Chemokine (C-X-C motif) ligand 16

0.008121

1.56